» Articles » PMID: 33240420

The Mechanism of and the Association Between Interleukin-27 and Chemotherapeutic Drug Sensitivity in Lung Cancer

Overview
Journal Oncol Lett
Specialty Oncology
Date 2020 Nov 26
PMID 33240420
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukins (ILs) are involved in the occurrence and development of numerous types of cancer, and serve a critical role in the development of effective cancer therapeutics. The aim of the present study was to investigate the effect of IL-27 on chemotherapy resistance in lung cancer cells, and analyze its potential molecular mechanism in lung cancer tissues. Western blot analysis and reverse transcription-quantitative polymerase chain reaction were performed to examine the RNA and protein expression levels of IL-27. A Cell Counting Kit-8 assay was performed to evaluate the proliferation rates of the lung cancer line A549. Flow cytometry was subsequently applied to determine the rate of apoptosis in A549 cells. The data obtained revealed that the expression of IL-27 with cisplatin, significantly suppressed the proliferation and apoptosis of A549 cells compared with that in the cisplatin treatment group alone. The expression of Akt and apoptosis factors such as Caspase-3 and Bcl-2/Bax also ascertained that upregulated IL-27 inhibited the development of cancer and increased apoptosis in the A549 cells. Therefore, IL-27 may represent a potential target for antitumor therapy, especially when considering the clinical challenges presented by the development of chemoresistance in tumors. These findings suggest that IL-27 is a promising biomarker and represents a novel treatment strategy for patients with lung cancer.

Citing Articles

Identification of a tumor immune-inflammation signature predicting prognosis and immune status in breast cancer.

Liu Y, Ouyang W, Huang H, Tan Y, Zhang Z, Yu Y Front Oncol. 2023; 12:960579.

PMID: 36713514 PMC: 9881411. DOI: 10.3389/fonc.2022.960579.


Activation of the TGF- Pathway Enhances the Efficacy of Platinum-Based Chemotherapy in Small Cell Lung Cancer Patients.

Lin A, Zhu L, Jiang A, Mou W, Zhang J, Luo P Dis Markers. 2023; 2022:8766448.

PMID: 36590751 PMC: 9798106. DOI: 10.1155/2022/8766448.


Exploring the role of interleukin-27 as a regulator of neuronal survival in central nervous system diseases.

Nortey A, Garces K, Hackam A Neural Regen Res. 2022; 17(10):2149-2152.

PMID: 35259821 PMC: 9083161. DOI: 10.4103/1673-5374.336134.


Integrative Characterization of the Role of IL27 In Melanoma Using Bioinformatics Analysis.

Dong C, Dang D, Zhao X, Wang Y, Wang Z, Zhang C Front Immunol. 2021; 12:713001.

PMID: 34733272 PMC: 8558420. DOI: 10.3389/fimmu.2021.713001.


The Role of the IL-6 Cytokine Family in Epithelial-Mesenchymal Plasticity in Cancer Progression.

Abaurrea A, Araujo A, Caffarel M Int J Mol Sci. 2021; 22(15).

PMID: 34361105 PMC: 8347315. DOI: 10.3390/ijms22158334.

References
1.
Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

2.
Lo Russo G, Proto C, Garassino M . Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?. Transl Lung Cancer Res. 2016; 5(1):110-4. PMC: 4758965. DOI: 10.3978/j.issn.2218-6751.2015.12.02. View

3.
Krevvata M, Shan X, Zhou C, Dos Santos C, Habineza Ndikuyeze G, Secreto A . Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells. Haematologica. 2018; 103(6):959-971. PMC: 6058784. DOI: 10.3324/haematol.2017.183202. View

4.
Zhu J, Liu J, Shi M, Cheng X, Ding M, Zhang J . IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. JCI Insight. 2018; 3(7). PMC: 5928864. DOI: 10.1172/jci.insight.98745. View

5.
Zhang Z, Zhou B, Zhang K, Song Y, Zhang L, Xi M . IL-27 suppresses SKOV3 cells proliferation by enhancing STAT3 and inhibiting the Akt signal pathway. Mol Immunol. 2016; 78:155-163. DOI: 10.1016/j.molimm.2016.09.014. View